Pediatrics, Phase I-II

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma (RELATIVITY-069)

Volunteers
Health Professionals

What is the purpose of this trial?

The purpose of this study is to assess the safety, tolerability, drug levels, and preliminary efficacy of relatlimab plus nivolumab in pediatric and young adult participants with recurrent or refractory classical Hodgkin lymphoma and non-Hodgkin lymphoma.

Find out more about who can participate in this trial

Contact Information

For more information about this study, including how to volunteer, contact Jessica Goepfert

Help Us Discover!

You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.

Create a volunteer profile

Principal Investigator

Stephanie Massaro, MD, MPH
Associate Professor of Pediatrics (Hematology/Oncology); Medical Director, Pediatric Hematology/Oncology; Director, Pediatric Palliative Care

Sub-Investigators

Last Updated
12/29/2023
Study HIC
#2000032969